Cosmetic composition containing Cyperus rotundus extract for anti-inflammatory, skin soothing, mitigating irritation and improving skin barrier

Abstract

The present invention relates to a cosmetic composition containing a Cyperus rotundus extract extracted by heating microbubbles. The extract has excellent anti-inflammatory effects by suppressing the production of nitric oxide (NO) and the expression of inflammation-inducing factors IL-6 (interleukin 6), COX-2 (cyclooxygenase-2), IL-1β (interleukin-1β), and TNF-α (tumor necrosis factor-α). It also enhances the expression of skin impact and moisturizing genes AQP-3 (aquaporin-3), HAS-2 (hyaluronan synthase 2), CLDN-1 (claudin-1), CDH1 (cadherin 1), FLG (filaggrin), and IVL (involucrin). When used as a cosmetic, it has excellent effects on skin soothing, moisturizing, improving the skin barrier, easing irritation such as skin erythema, and relieving itching, and can be usefully used as a multi-care product that improves skin condition.

Description

[Technical field]

[0001] The present invention relates to a cosmetic composition for anti-inflammatory, skin soothing, mitigating irritation and improving skin barrier properties, which contains a nut sedge extract produced by a microbubble extraction method. [Background technology]

[0002] Cyperus rotundus is a perennial herb belonging to the Cyperaceae family that grows wild in southern Korea and Jeju Island and contains essential oil components such as pinene, camphene, 1,8-cineol, and limonene, and is known to have analgesic and antibacterial properties. However, since it is extracted using a static extraction method that uses existing solvents, there may be some limitations in utilizing the active ingredients of Cyperus rotundus.

[0003] Microbubbles are used in a variety of fields for sterilization, cleaning, and other applications, taking advantage of their physicochemical properties, such as gas dissolution, self-pressurization, and electrostatic charge, as well as the oxidation-reduction action of ultra-fine bubbles and the large amount of energy generated when the bubbles disappear.

[0004] In recent years, products and services that utilize the functionality of microbubbles alone have been developed, and the fields in which they are used are expanding. They are widely used in all fields of industry, including food, medicine, agriculture, fisheries, and dyeing. Microbubbles are also used to extract natural raw materials, as in Korea Patent No. 10-2222661.

[0005] In the course of researching the various physiological activities of Cyperus rotundus, the present inventors confirmed that a microbubble-extracted Cyperus rotundus extract has higher anti-inflammatory, skin soothing, irritation relief and skin barrier improving effects than existing static extracts, and found that this can be used as a new cosmetic composition, thus completing the present invention. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Korean Patent Publication No. 2013-0062112 (Name of invention: Skin topical composition for preventing and treating inflammatory diseases containing nutmeg extract as an active ingredient, Applicant: Korea Oriental Medicine Industry Promotion Foundation, Publication date: June 12, 2013) [Patent Document 2] Korean Patent No. 10-2222661 (Name of invention: Method for producing extracts of natural cosmetic ingredients using heated microbubbles and cosmetic composition containing the same, Applicant: J2K Bio Co., Ltd., Date of registration: August 24, 2020) [Patent Document 3] US Patent No. 11110117 (Name of invention: Skin preparation composition for external use containing complex hyaluronic acid, Applicant: J2K Bio Co., Ltd., Date of registration: September 7, 2021) Summary of the Invention [Problem to be solved by the invention]

[0007] An object of the present invention is to provide a cosmetic composition for anti-inflammatory, skin soothing, mitigating irritation and improving skin barrier properties, which contains an extract of Cyperus rotundus produced by a microbubble extraction method. [Means for solving the problem]

[0008] The present invention relates to an anti-inflammatory and skin-soothing cosmetic composition containing a warm microbubble extracted extract of Cyperus rotundus. The extract may contain 50,000 to 60,000 ppm of α-cyperone.

[0009] Preferably, the extract is characterized by suppressing the production of nitric oxide (NO) and is effective in inhibiting the expression of a gene selected from the group consisting of inflammatory factors interleukin 6 (IL-6), cyclooxygenase-2 (COX-2), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α).

[0010] The extract may have a skin barrier improving effect. In addition, the extract may have a moisturizing effect by suppressing transepidermal water loss and increasing skin moisture content. Preferably, the extract enhances the expression of a gene selected from the group consisting of AQP-3 (Aquaporin-3), HAS-2 (Hyaluronan Synthase 2), CLDN-1 (claudin-1), CDH1 (Cadherin 1), FLG (Filaggrin), and IVL (involucrin).

[0011] The extract may also have the effect of mitigating skin irritation. Preferably, the extract relieves skin erythema or improves itching, relieves skin irritation, and soothes the skin.

[0012] The heated microbubble extraction can be carried out using a microbubble generator having a pore size of 5 to 50 μm and a discharge amount (or liquid flow rate) of 1.0 to 1.2 Ton / hr, and extraction with an organic solvent at 40 to 60° C. for 3 to 5 hours. In this case, the extraction efficiency is best when the microbubbles are generated under the conditions of a pressure of 3 to 4 bar and a gas flow rate of 3 to 4 L / min.

[0013] The organic solvent may be a C1 to C4 alcohol or an aqueous solution thereof. The C1 to C4 alcohol may be methanol, ethanol, propanol, isopropanol, butanol, or isobutanol, and the aqueous solution of the C1 to C4 alcohol may be a 40 to 60% (v / v) aqueous solution of the C1 to C4 alcohol. The organic solvent may be used in an amount of 1 to 40 times the weight of the nutsedge used (1 to 40 L per 1 kg).

[0014] The extract of the present invention may include a fraction thereof. The term "fraction" as used in the present invention means a product obtained by fractionation to separate a specific component or a specific group of components from a mixture containing various components.

[0015] The fractionation method for obtaining the fraction of the present invention is not particularly limited, and may be performed according to a method commonly used in the art. A solvent fractionation method in which various solvents are treated, an ultrafiltration fractionation method in which a sample is passed through an ultrafiltration membrane having a certain molecular weight cut-off value, a chromatographic fractionation method in which various chromatographies (made for separation by size, charge, hydrophobicity, or affinity) are performed, and a combination thereof may be employed. The type of fractionation solvent used to obtain the fraction of the present application is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of fractionation solvents of the present application include polar solvents such as water and alcohols having 1 to 4 carbon atoms; and non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of one or more of them.

[0016] The chromatography can be selected from silica gel column chromatography, LH-20 column chromatography, ion exchange resin chromatography, medium pressure liquid chromatography, thin layer chromatography (TLC), silica gel vacuum liquid chromatography, and high performance liquid chromatography.

[0017] The present invention also provides a pharmaceutical composition for anti-inflammatory, skin soothing, alleviating irritation, and improving skin barrier properties, which contains a heated microbubble-extracted nutmeg extract. The nutmeg extract can be added to the pharmaceutical composition of the present invention in an amount of 0.001 to 100% by weight.

[0018] The pharmaceutical compositions can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injectable solutions by a conventional method. Carriers, excipients, and diluents that can be included in the pharmaceutical compositions include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When formulated, they are prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations are prepared by mixing the nutsedge extract of the present invention with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, liquid preparations, emulsions, syrups, etc., and may contain various excipients such as wetting agents, sweeteners, flavoring agents, preservatives, etc. in addition to water and liquid paraffin, which are commonly used simple diluents. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As a suppository base, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin, etc. can be used.

[0019] The dosage of the pharmaceutical composition of the present invention will vary depending on the age, sex and weight of the subject to be treated, the particular disease or pathological condition to be treated, the severity of the disease or pathological condition, the route of administration and the prescriber's judgment. Determination of dosage based on such factors is within the level of one skilled in the art, and generally, dosages range from 0.01 mg / kg / day to about 2000 mg / kg / day. More preferably, dosages range from 1 mg / kg / day to 500 mg / kg / day. Administration may be once a day or in several divided doses. The dosages mentioned above are not intended to limit the scope of the present invention in any respect.

[0020] The pharmaceutical composition of the present invention can be administered to mammals such as rats, livestock, and humans by various routes. Any administration method is conceivable, for example, oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dura or intracerebrovascular injection. The nutsedge extract of the present invention is a drug that can be safely used for prophylactic purposes for a long period of time because it has almost no toxicity or side effects.

[0021] The present invention also provides a health functional food for anti-inflammatory, skin soothing, irritation relief and skin barrier improvement, comprising a heated microbubble extracted nutmeg extract and a food-scientifically acceptable food supplement additive. The nutmeg extract can be added to the health functional food of the present invention at 0.001 to 100% by weight. The health functional food of the present invention includes forms such as tablets, capsules, pills and liquids, and examples of foods to which the extract of the present invention can be added include various drinks, meat, sausage, bread, candies, snacks, noodles, ice cream, dairy products, soups, ion drinks, drinking water, alcoholic drinks, gum, tea and vitamin complexes.

[0022] The cosmetic composition containing the nutmeg extract extracted using heated microbubbles of the present invention can be manufactured in any formulation commonly used in the art, and can be provided in any formulation selected from serum, milky lotion, emulsion, face pack, hand cream, foot cream, lip balm, lipstick, eye shadow, eyeliner, eyebrow pencil, blusher, highlighter, general lotion, lotion, cream, serum, cosmetic soap, softening lotion, medicated lotion, whole body cleanser, cleansing foam, cleansing lotion, gel, cleansing oil, cleansing cream, shampoo, rinse, hair treatment, hair lotion, cleansing tissue, and cleansing water.

[0023] More specifically, when the cosmetic composition of the present invention is in the form of a paste, cream or gel, the carrier component may be an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tragacanth, a cellulose derivative, a polyethylene glycol, a silicone, a bentonite, a silica, a talc or a zinc oxide. When the cosmetic composition of the present invention is in the form of a powder or a spray, the carrier component may be lactose, talc, silica, aluminum hydroxide, calcium silicate or a polyamide powder, and in particular in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane-butane or dimethyl ether may be further included. When the cosmetic composition of the present invention is in the form of a solution or emulsion, the carrier component may be a solvent, a solvating agent or an emulsifier, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, aliphatic glycerol esters, polyethylene glycol or fatty acid esters of sorbitan. When the cosmetic composition of the present invention is in the form of a suspension, the carrier component may be a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. When the cosmetic composition of the present invention is in the form of a surfactant-containing cleanser, the carrier component may be a fatty alcohol sulfate, a fatty alcohol ether sulfate, a sulfosuccinic acid monoester, acetionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamide betaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester. The cosmetic composition of the present invention may further contain excipients including fluorescent substances, fungicides, hydrotropes, moisturizers, fragrances, fragrance carriers, proteins, solubilizers, sugar derivatives, UV protection agents, vitamins, plant extracts, and the like.The amount of these ingredients added can be selected according to the formulation or purpose of use within a range that does not impair the inherent effects of the cosmetic composition. The amount of the ingredients added can be, for example, 0.1 to 10% by weight, preferably 0.1 to 6% by weight, based on the total weight of the composition, but is not limited thereto. Effect of the Invention

[0024] The present invention relates to a cosmetic composition containing a Cyperus rotundus extract extracted by heating microbubbles. The extract has excellent anti-inflammatory effects by suppressing the production of nitric oxide (NO) and the expression of inflammation-inducing factors IL-6 (interleukin 6), COX-2 (cyclooxygenase-2), IL-1β (interleukin-1β), and TNF-α (tumor necrosis factor-α). It also enhances the expression of skin impact and moisturizing genes AQP-3 (aquaporin-3), HAS-2 (hyaluronan synthase 2), CLDN-1 (claudin-1), CDH1 (cadherin 1), FLG (filaggrin), and IVL (involucrin). When used as a cosmetic, it has excellent effects on skin soothing, moisturizing, improving the skin barrier, easing irritation such as skin erythema, and relieving itching, and can be usefully used as a multi-care product that improves skin condition. [Brief description of the drawings]

[0025] [Figure 1] 1 is a graph showing the results of a cream containing the nutmeg extract extracted by heating and microbubbles according to the present invention, which has an effect of relieving itching. [Diagram 2] 1 is a graph showing the results of a cream containing the nutmeg extract extracted by heating and microbubbles according to the present invention, which has an effect of inhibiting transepidermal water loss. [Diagram 3] 1 is a graph showing the results of a cream containing the nutmeg extract extracted by heating and microbubbles according to the present invention, which has an effect of increasing skin moisture content. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, this description is provided so that this description will be thorough and complete, and will fully convey the concept of the present invention to those skilled in the art. EXAMPLES

[0027] <Examples 1 to 3. Production of Cyperus nutmeg microbubble extract> Cyperus Rotundus Root was purchased from Samhong Dry Materials Pharmaceutical Co., Ltd. (Korea). 100g of Cyperus Rotundus Root was injected into a microbubble generator (manufacturer: O2BUBBLE) with a pore size of 5-50μm and a discharge rate (liquid flow rate) of 1.0-1.2Ton / hr together with 2000g of 50(v / v)% ethanol aqueous solution (weight ratio of 1:20) as a solvent to extract microbubbles, which were then filtered through a filter with a pore size of 5μm (No. 2, HYUNDAI MICRO), concentrated to dryness, and vacuum dried to prepare the sample.

[0028] At this time, when bubbles were generated in the microbubble generator using air in the atmosphere (Air), the pressure was set to 3 to 4 bar, and the air flow rate was set to 3 to 4 L / min. [Table 1]

[0029] <Comparative Examples 1 to 13. Preparation of extracts under comparative conditions> A nut sedge extract was produced, and the extraction method was carried out under different conditions as follows. [Table 2]

[0030] <Experimental Example 1. Confirmation of the active ingredients in each extract> The standard of α-cyperone, an indicator component in the extract, was purchased from Sigma Aldrich. 10 mg of the standard was dissolved in 100 ml of 99% methanol, and 50 mg of each sample was dissolved in 50 ml of 99% methanol.

[0031] The analytical system used was a Waters e2695 / 2998 UVD, and the column was a Capcellpak C18 UG 120 (5 μm, 4.6 × 250 mm). The elution gradient solvent was 0.1% formic acid aqueous solution as solvent A and ACN as solvent B, and the elution was performed in 13 steps from solvent A to solvent B at 100:0 (v:v) → 0:100 (v:v) for 80 minutes.

[0032] The final content of the active ingredient in each sample is shown in Table 3 below. [Table 3] From the results in Table 3 above, it can be confirmed that the extracts of Examples 1 to 3 of the present invention contain the active compound α-cyperone at the highest content.

[0033] <Experimental Example 2. Confirmation of cytotoxicity of sample> To confirm the cytotoxicity of each extract prepared in Examples 1 to 3 and Comparative Examples 1 to 13, an MTT assay was performed. First, 5 × 10 RAW264.7 cells were placed in a 96-well plate. 4 After dispensing at cell / well, samples dissolved in DMSO were added to each concentration after 24 hours. After 24 hours, the medium was removed, and 40 μL of MTT reagent (in PBS 2.5 mg / mL) was added to each well. After 4 hours in an incubator, the supernatant was removed. 100 μL of DMSO was dispensed to each well to completely dissolve the samples. The absorbance was measured at 540 nm using a spectrophotometer.

[0034] [Table 4]

[0035] As a result, as shown in Table 4, when the value of the control group was taken as 100%, the cell viability of each extract was confirmed to be 97.0% or more up to the maximum concentration of 250 μg / ml, and it was confirmed that the extract had no cytotoxicity. Subsequent experiments were carried out at concentrations of 250 μg / ml or less.

[0036] <Experimental Example 3. Measurement of Nitric Oxide Production> To confirm the nitric oxide (NO) production inhibitory activity of each extract prepared in Examples 1 to 3 and Comparative Examples 1 to 13, an experiment was carried out using mouse macrophage cells, RAW264.7 cell line. RAW264.7 cells were plated in a 96-well plate at 1.0 × 10 4 The cells were dispensed at 100 cells / well and cultured for 24 hours in an incubator at 37°C and supplied with 5% CO2.

[0037] After that, serially diluted samples and stimulants were treated in a 96-well plate. The final concentration of the stimulant LPS was set to 1 μg / mL. 100 μL of the supernatant of the cells that had been cultured for 24 hours was taken and placed in a new 96-well plate. Griess A and Griess B reagents were mixed in a 1:1 ratio and 100 μL was added to each well. The reaction was allowed to proceed at room temperature for 10 minutes, and the absorbance was measured at 540 nm.

[0038] Nitric oxide production was calculated using the following formula: NO generation rate (%)=(Sample absorbance / Control absorbance)×100 To show the measurement results, the OD value of cells treated with 1 μg / mL of LPS was converted to 100%, and this value was shown as the control.

[0039] [Table 5]

[0040] As a result, as shown in Table 5, it was confirmed that the extracts of Examples 1 to 3 of the present invention exhibited a concentration-dependent inhibitory effect on nitric oxide production, while extracts that did not meet this standard were deemed to have low anti-inflammatory efficacy because they did not significantly inhibit nitric oxide production.

[0041] <Experimental Example 4. Investigation of anti-inflammatory related gene expression levels> RAW264.7 cells were cultured in a 6-well plate at 4.0 x 10 5 The cells were dispensed at 100 cells / well and cultured for 24 hours in a 37°C incubator with 5% CO2. Each extract sample was treated to a final concentration of 100 ppm, and LPS was added as a stimulant at 1 μg / mL for 4 hours. The medium supernatant was removed, washed with PBS, and dissolved in 500 μL of NucleoZOL (Macherey-nagel, Germany). Then, 200 μL of sterile distilled water was added and centrifuged for 15 minutes, and 500 μL of the supernatant was transferred to a new tube. Next, 500 μL of isopropanol was added and centrifuged for 10 minutes, the supernatant was removed, and 75% (v / v) ethanol aqueous solution was added and centrifuged again for 5 minutes. The supernatant was removed and dried at room temperature, and then 50 μL of diethylpyrocarbonate-distilled water (DEPC-DW) was dispensed and dissolved, and RNA was quantified using a spectrophotometer.

[0042] Then, 1 μg of RNA quantified using the HiSenScriptTM RH(-) RT PreMix Kit was added and mixed with DEPC-DW to make the total volume 20 μL. cDNA was synthesized under the conditions of 42°C for 30 minutes, 85°C for 10 minutes, and 4°C infinity. The synthesized complementary DNA (cDNA) was mixed with 10 μL of 2x Real-Time PCR Master Mix (BioFACT), 1 μL of cDNA, 1 μL of forward primer (10 pmole / μL), 1 μL of reverse primer (10 pmole / μL), and DEPC-DW to make the total volume 20 μL. The primers for the genes to be confirmed were those disclosed in Table 6 below.

[0043] [Table 6]

[0044] Then, PCR was performed using a real-time PCR device under the following conditions: 95°C for 15 minutes, 95°C for 20 seconds, and 60°C for 40 seconds (50 cycles).The experimental results were analyzed for the mRNA expression of each factor by relative quantitative analysis (△Ct value).

[0045] The analysis results of the expression level of each gene are shown in Table 7 below. [Table 7]

[0046] As a result, as shown in Table 7, it was found that the gene expression for the inflammatory factors IL-6 (interleukin 6), COX-2 (cyclooxygenase-2), IL-1β (interleukin-1β), and TNF-α (tumor necrosis factor-α) was significantly suppressed in the groups treated with the extracts of Examples 1 to 3.

[0047] <Experimental Example 5: Confirmation of gene expression levels related to skin barrier and moisturizing> Next, to confirm the skin impact enhancement effect, HaCaT cells were cultured in 6-well plates at 2.0 × 10 5 The cells were dispensed at 100 cells / well and cultured for 24 hours in a 37°C incubator supplied with 5% CO2. After washing with PBS and replacing with DMEM medium without FBS, each extract sample was treated so that the final concentration was 100 ppm. RNA was extracted and cDNA was synthesized in the same manner as in the anti-inflammatory gene measurement conditions, and the gene expression of AQP-3 (Aquaporin-3), HAS-2 (Hyaluronan Synthase 2), CLDN-1 (claudin-1), CDH1 (Cadherin 1), FLG (Filaggrin), and IVL (involucrin) was confirmed in the same experiment. The primers used at this time are as shown in Table 8 below, and the gene expression is shown in Table 9, with the comparison group (untreated group) set to 100%.

[0048] [Table 8]

[0049] [Table 9]

[0050] As shown in Table 9, the gene expression profiles of AQP-3 (Aquaorin-3), HAS-2 (Hyaluronan Synthase 2), CLDN-1 (claudin-1), CDH1 (Cadherin 1), FLG (Filaggrin) and IVL (involucrin), which are related to strengthening the skin barrier and moisture / hydration, were analyzed. As a result, it can be seen that the extracts of Examples 1 to 3 of the present invention are most suitable for use as cosmetic compositions that enhance the skin's moisturizing function and strengthen the skin barrier.

[0051] <Example of cosmetic composition formulation 1. Preparation of lotion> A lotion was prepared using a conventional method with the following contents: 5.0% by weight of the extract of Example 1, 5.2% by weight of propylene glycol, 1.5% by weight of oleyl alcohol, 3.2% by weight of ethanol, 3.2% by weight of polysorbate 20, 2.0% by weight of benzophenone-9, 1.0% by weight of carboxyvinyl polymer, 3.5% by weight of glycerin, a trace amount of fragrance, a trace amount of preservatives, and the remaining amount of purified water.

[0052] <Cosmetic composition formulation example 2. Production of emulsion> An emulsion was prepared using a conventional method with the following contents: 5.0% by weight of the extract of Example 1, 1.0% by weight of cetostearyl alcohol, 0.8% by weight of glyceryl monostearate, 0.3% by weight of sorbitan monostearate, 1.0% by weight of polysorbate 60, 5.0% by weight of mineral oil, 3.0% by weight of cyclomethicone, 0.5% by weight of dimethicone, 0.1% by weight of allantoin, 5.0% by weight of glycerin, 2% by weight of alcohol, 3.0% by weight of propylene glycol, a trace amount of fragrance, a trace amount of preservatives, and the remaining amount of purified water.

[0053] <Cosmetic Composition Formulation Example 3: Production of Toner> A toner was prepared using a conventional method with the following contents: 5.0% by weight of the extract of Example 1, 4.0% by weight of propylene glycol, 3.0% by weight of glycerin, 0.5% by weight of allantoin, 0.01% by weight of EDTA-2Na, 5.0% by weight of ethanol, 1.5% by weight of triethanolamine, 2.0% by weight of squalane, 2.5% by weight of beeswax, 1.0% by weight of polysorbate 60, 1.0% by weight of carboxyl vinyl polymer, 2.5% by weight of sorbitan sesquioleate, a trace amount of fragrance, a trace amount of preservative, and the remaining amount of purified water.

[0054] <Cosmetic composition formulation example 4. Production of cream> A cream was prepared using a conventional method with the following contents: 5.0% by weight of the extract of Example 1, 0.7% by weight of polyoxyethylene sorbitan monostearate, 0.5% by weight of sorbitan sesquioleate, 0.6% by weight of cetyl alcohol, 0.75% by weight of stearic acid, 0.6% by weight of glyceryl monostearate, 15.0% by weight of liquid paraffin, 10.0% by weight of carboxyvinyl polymer, 0.2% by weight of triethanolamine, a trace amount of fragrance, a trace amount of preservatives, and the remaining amount of purified water.

[0055] <Experimental Example 6: Confirmation of skin irritation relief effect> The toner produced in Cosmetic Composition Formulation Example 3 was used to carry out a human body patch test to evaluate the skin irritation mitigation effect.

[0056] To this end, 20 adult female subjects aged 20 to 55 years were selected as test subjects (day -1, the start of the test). The test areas were washed, the skin was allowed to settle for 30 minutes, and then an evaluation was performed using a spectrophotometer.

[0057] At this time, a chamber soaked in a 1.0% aqueous solution of SLS (sodium lauryl sulfate) was attached to the test site for 24 hours to induce skin erythema. After removing the chamber from the test site, the condition of the test site was checked (before product use, day 0).

[0058] After inducing erythema, the test subjects were then given instructions on how to use the toner and the test product was applied. After 24, 48, and 72 hours of product use, safety and instrumental evaluations were conducted on the test subjects to evaluate efficacy. The results showed that the *a value was measured using a spectrophotometer and that it was significantly reduced after 72 hours of product use.

[0059] [Table 10]

[0060] As shown in the results of Table 10, the area where SLS was applied alone showed maximum redness of the skin after 24 hours, but when the product containing the Cyperus nutmeg extract obtained in Example 1 was applied, the skin condition quickly recovered. However, in the case of the toner that did not contain the extract, redness remained even after 72 hours.

[0061] <Experimental Example 7: Visual Evaluation by Experts> The cream of Formulation Example 4 (containing 5% by weight of the Cyperus nutmeg extract of Example 1) was compared with a cream containing the same ingredients but not the extract to test its clinical efficacy. This experiment was conducted on the same subjects as in the user evaluation.

[0062] For this purpose, subjects who complained of itching were asked to apply an appropriate amount of each cream twice a day, in the morning and evening, for a test period of 8 weeks to an area within 5 cm below the knee of the subjects who complained of itching. A total of 32 subjects were tested.

[0063] First, a specialist (dermatologist / specialist) evaluated the degree of erythema, keratinization, induration, and fissuring using the ESIF scale (erythema, scaling, induration, fissuring) in Table 11 below.

[0064] [Table 11]

[0065] According to the expert evaluation, four variables were added and each subject could score a total of 0 to 12 points. If the subject scored more than 6 points, he / she could be deemed to require dermatological treatment and could be excluded from the study.

[0066] As a result of the check, the 32 test subjects were checked for erythema, keratin, induration, and cracking for a total of 8 weeks, and no subjects were found to have scores above 6. As no subjects were found to be unsuitable for the experiment or to have side effects, the experiment was continued. No related results are attached.

[0067] <Experimental Example 8: Confirmation of improvement of itching> The itching sensation of the subjects who underwent the 8-week experiment was evaluated using a visual analogue scale (VAS), in which the subjects directly marked a 10 cm line and then measured its length. The rate of change in the itching scale was reflected by the following formula: *Before using the product: 0 weeks Change in itching scale (%) = {(itchiness scale after using the product - itchiness scale before using the product) / itchiness scale before using the product} x 100 The results are shown in FIG.

[0068] FIG. 1 shows that the TEST cream containing Cyperus nutmeg extract showed a significant itching relief effect at weeks 4 and 8 compared to the CONTROL cream, which was not treated with the extract.

[0069] <Experimental Example 9: Confirmation of transepidermal water loss> The transepidermal water loss (TEWL) depending on the degree of cream use was tested in accordance with the Complainant's Guide, a guideline for human application testing of cosmetics that helps to improve itching by restoring the function of the skin barrier. The equipment used to measure transepidermal water loss was a Vapometer (Delfin, Finland). The Vapometer has a chamber that can measure the relative humidity of the skin surface, making it possible to measure the amount of water loss on the skin surface. The lower the transepidermal water loss (TEWL), the lower the measurement value, and the unit of measurement is g / m. 2 / h, and the results are shown in Figure 2 according to the following formula. *Before using the product: 0 weeks Skin moisture content change rate (%) = {(Measurement value after product use - Measurement value before product use) / Measurement value before product use} x 100

[0070] Figure 2 shows that TEST cream containing Cyperus nutmeg extract significantly reduced transepidermal water loss at 4 and 8 weeks compared to CONTROL cream, which was not treated with the extract.

[0071] <Experimental Example 10: Confirmation of skin moisture content> The moisture content of skin depending on the amount of cream used was measured using a Corneometer CM825 (Courage-Khazaka electronic GmbH, Germany). The Corneometer measures the capacitance of the current transmitted through a probe that contacts the skin. The moisture content and capacitance are proportional to each other, so the higher the moisture content, the higher the measured value, and the measurement coefficient is in arbitrary units (AU). The results were converted using the following formula and are shown in Figure 3. *Before using the product: 0 weeks Skin moisture content change rate (%) = {(Measurement value after product use - Measurement value before product use) / Measurement value before product use} x 100 Referring to FIG. 3, it can be seen that the skin moisture content also increased significantly in the group that applied the cream containing the Cyperus nutmeg extract of the present invention.

[0072] <Experimental Example 11: Satisfaction of test subjects> After using the cream containing the nutmeg extract of the present invention and the control cream for 4 weeks, the product satisfaction of the users was measured according to the criteria in Table 12 below, and the results are shown in Table 13.

[0073] [Table 12]

[0074] [Table 13] As can be seen from the results in Table 13, the cream containing the extract of the present invention not only has an effect of alleviating itching, but also has a high preference for the cosmetic formulation itself. From these results, the usefulness of the cream containing the Cyperus nutmeg extract of the present invention was confirmed.

Claims

1. An anti-inflammatory and skin-soothing cosmetic composition comprising a warm microbubble extracted extract of Cyperus rotundus.

2. 2. The anti-inflammatory and skin-soothing cosmetic composition according to claim 1, characterized in that it contains α-cyperone.

3. The anti-inflammatory and skin-soothing cosmetic composition according to claim 1, characterized in that the extract inhibits the production of nitric oxide (NO).

4. The anti-inflammatory and skin-soothing cosmetic composition according to claim 1, characterized in that the extract inhibits the expression of a gene selected from the group consisting of inflammation-inducing factors IL-6 (interleukin 6), COX-2 (cyclooxygenase-2), IL-1β (interleukin-1β), and TNF-α (tumor necrosis factor-α).

5. The anti-inflammatory and skin-soothing cosmetic composition according to claim 1, wherein the extract has a skin barrier improving effect.

6. The anti-inflammatory and skin-soothing cosmetic composition according to claim 1, characterized in that the extract enhances the expression of a gene selected from the group consisting of AQP-3 (Aquaporin-3), HAS-2 (Hyaluronan Synthase 2), CLDN-1 (claudin-1), CDH1 (Cadherin 1), FLG (Filaggrin) and IVL (Involucrin).

7. The anti-inflammatory and skin-soothing cosmetic composition according to claim 1, wherein the extract has skin irritation relieving efficacy.

8. 8. The anti-inflammatory and skin-soothing cosmetic composition according to claim 7, wherein the skin irritation is erythema or itching.

Images